{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'recommended that patients continue with their standard BPA regimens for the first 7 days', 'following initiation of fitusiran dosing, with institution of the protocol-specific bleed', 'management guidelines with reduced BPA at Day 8 and beyond (Table 4).', 'Patients on fitusiran will be provided a written bleed management plan with appropriate dosing', 'of BPA for use during Day 1 through 7, as well as a bleed management plan with dosing for', 'Day 8 and beyond. Thereafter the bleed management plan will be reviewed and updated at', 'monthly visits, and new written plans provided to the patient if dosing changes.', 'Importantly, during the treatment period, patients should not use BPA or other hemostatic agents', 'as prophylaxis for bleeding episode prevention, including doses related to anticipated hemostatic', 'challenges such as physical activity. For prophylaxis of bleeding episodes in patients who', 'require operative procedures (see Section 6.6).', 'Bleed Management Guidelines Day 1 to Day 7: Patients should be instructed to call the site', 'prior to administering factor or BPA. Patients should continue with their standard BPA', 'regimens.', 'Bleed Management Guidelines Day 8 and Beyond:', 'When a patient experiences symptoms that may be consistent with bleeding episodes, the', 'following steps should be followed:', '1. Patient should be instructed to call the study center to discuss symptoms to determine', 'whether or not they are consistent with a bleeding event and to discuss the appropriate', 'factor/BPA dose to use. This interaction between patient and Investigator is', 'recommended prior to the administration of each dose of factor or BPA. Confirmation of', 'bleeds at the study center prior to treatment may be considered. Such visits should', 'capture assessments per Section 6.4 and Table 2.', '2.', 'If a determination is made that symptoms require treatment, the recommended treatment', 'algorithm for bleeding episodes is described below:', '1. A single dose can be administered according to the guidelines in Table 4.', '2. The patient should be instructed to re-evaluate symptoms in 24 hours for bleeds', 'treated with FVIII, FIX or aPCC and in 2-3 hours for bleeds treated with rFVIIa.', 'a. Administration of FIX Extended half-life should not be more frequent than', 'every 5-7 days.', '3. If a second dose (in the case of FVIII, FIX or aPCC) or a third dose (in the case of', 'rFVIIa) is needed, the patient must call the study center before dosing.', 'a. Consider evaluation and treatment of the patient at the study center and', 'confirmation of bleeds when any repeated doses are needed (See Section 6.4', 'and Table 2).', 'b. If more than two doses of FVIII, FIX or aPCC or three doses of rFVIIa are', 'needed, the patient should be seen at the study center within 48-72 hours.', '4. Doses should not be administered at less than 24 hour intervals (except rFVIIa as', 'indicated in Table 4).', 'Property of the Sanofi Group - strictly confidential', '47']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '5. Doses should not exceed the protocol maximum recommended dose indicated in', 'Table 4.', '6. Consultation with the study Medical Monitor and Clinical Advisor should be', 'considered for clinical circumstances below, that may warrant AT replacement:', 'a. Doses of factor or BPA higher than those recommended in Table 4', 'b. Dosing of factor or BPA at decreased intervals than those recommended in', 'Table 4', 'c. Multiple or repeated doses of factor or BPA', '7. Antifibrinolytics may not be used in combination with factor or BPA.', 'Property of the Sanofi Group - strictly confidential', '48']\n\n###\n\n", "completion": "END"}